ProfileGDS5678 / 1452081_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 54% 56% 53% 54% 54% 63% 55% 54% 57% 53% 55% 55% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4584956
GSM967853U87-EV human glioblastoma xenograft - Control 23.348754
GSM967854U87-EV human glioblastoma xenograft - Control 33.39656
GSM967855U87-EV human glioblastoma xenograft - Control 43.2542253
GSM967856U87-EV human glioblastoma xenograft - Control 53.3038954
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4507254
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8384563
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3496955
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3344754
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4521357
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3053853
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3375655
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3694355
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6845262